Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLT NASDAQ:FENC NASDAQ:LYEL NASDAQ:RAPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLTApplied Therapeutics$0.43+3.4%$0.47$0.30▼$10.62$61.93M2.062.44 million shs439,307 shsFENCAdherex Technologies$8.85+2.1%$8.64$3.96▼$9.42$247.00M0.5875,304 shs57,635 shsLYELLyell Immunopharma$13.22+0.7%$11.13$7.65▼$32.00$253.96M-0.1977,941 shs34,312 shsRAPTRapt Therapeutics$17.63+1.2%$11.46$5.67▼$26.56$291.57M-0.1110,921 shs144,394 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLTApplied Therapeutics-1.09%-5.52%-13.17%+20.58%-91.49%FENCAdherex Technologies-1.03%-3.88%+3.71%+12.31%+58.50%LYELLyell Immunopharma+2.42%+0.77%+24.10%+35.36%-46.63%RAPTRapt Therapeutics+7.40%+31.17%+48.38%+122.19%+11.67%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLTApplied Therapeutics$0.43+3.4%$0.47$0.30▼$10.62$61.93M2.062.44 million shs439,307 shsFENCAdherex Technologies$8.85+2.1%$8.64$3.96▼$9.42$247.00M0.5875,304 shs57,635 shsLYELLyell Immunopharma$13.22+0.7%$11.13$7.65▼$32.00$253.96M-0.1977,941 shs34,312 shsRAPTRapt Therapeutics$17.63+1.2%$11.46$5.67▼$26.56$291.57M-0.1110,921 shs144,394 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLTApplied Therapeutics-1.09%-5.52%-13.17%+20.58%-91.49%FENCAdherex Technologies-1.03%-3.88%+3.71%+12.31%+58.50%LYELLyell Immunopharma+2.42%+0.77%+24.10%+35.36%-46.63%RAPTRapt Therapeutics+7.40%+31.17%+48.38%+122.19%+11.67%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLTApplied Therapeutics 2.50Moderate Buy$6.101,318.60% UpsideFENCAdherex Technologies 3.00Buy$13.3350.66% UpsideLYELLyell Immunopharma 1.50Reduce$15.0013.46% UpsideRAPTRapt Therapeutics 2.50Moderate Buy$21.5722.36% UpsideCurrent Analyst Ratings BreakdownLatest APLT, FENC, RAPT, and LYEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/22/2025RAPTRapt TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/21/2025FENCAdherex TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.008/15/2025FENCAdherex TechnologiesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/15/2025FENCAdherex TechnologiesCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $14.008/12/2025RAPTRapt TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetNeutral$8.00 ➝ $9.008/8/2025RAPTRapt TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$51.00 ➝ $38.007/30/2025RAPTRapt TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Neutral$14.007/22/2025RAPTRapt TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$31.007/10/2025RAPTRapt TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.006/24/2025LYELLyell ImmunopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$10.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLTApplied Therapeutics$121K511.78N/AN/A$0.49 per share0.88FENCAdherex Technologies$47.54M5.20$0.03 per share271.24($0.21) per share-42.14LYELLyell Immunopharma$60K4,232.60N/AN/A$26.21 per share0.50RAPTRapt TherapeuticsN/AN/AN/AN/A$11.51 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLTApplied Therapeutics-$105.62M-$0.45N/AN/AN/AN/A-354.24%-144.16%11/6/2025 (Estimated)FENCAdherex Technologies-$440K-$0.42N/AN/AN/A-35.05%N/A-23.92%11/6/2025 (Estimated)LYELLyell Immunopharma-$342.99M-$24.29N/AN/AN/A-552,328.31%-85.58%-68.85%11/6/2025 (Estimated)RAPTRapt Therapeutics-$129.87M-$14.17N/AN/AN/AN/A-67.92%-59.59%11/11/2025 (Estimated)Latest APLT, FENC, RAPT, and LYEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025FENCAdherex Technologies-$0.06-$0.11-$0.05-$0.11$9.52 million$9.76 million8/13/2025Q2 2025APLTApplied Therapeutics-$0.17-$0.15+$0.02-$0.15$0.42 millionN/A8/12/2025Q2 2025LYELLyell Immunopharma-$3.80-$2.89+$0.91-$2.89$0.00 million$0.01 million8/7/2025Q2 2025RAPTRapt Therapeutics-$0.61-$0.65-$0.04-$0.65N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLTApplied TherapeuticsN/AN/AN/AN/AN/AFENCAdherex TechnologiesN/AN/AN/AN/AN/ALYELLyell ImmunopharmaN/AN/AN/AN/AN/ARAPTRapt TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLTApplied TherapeuticsN/A1.941.94FENCAdherex TechnologiesN/A4.854.59LYELLyell ImmunopharmaN/A7.657.65RAPTRapt TherapeuticsN/A13.2513.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLTApplied Therapeutics98.31%FENCAdherex Technologies55.51%LYELLyell Immunopharma66.05%RAPTRapt Therapeutics99.09%Insider OwnershipCompanyInsider OwnershipAPLTApplied Therapeutics1.60%FENCAdherex Technologies10.98%LYELLyell Immunopharma22.30%RAPTRapt Therapeutics2.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLTApplied Therapeutics30144.01 million141.71 millionOptionableFENCAdherex Technologies1027.91 million24.85 millionOptionableLYELLyell Immunopharma27019.21 million14.93 millionOptionableRAPTRapt Therapeutics8016.54 million15.45 millionOptionableAPLT, FENC, RAPT, and LYEL HeadlinesRecent News About These CompaniesRapt Therapeutics $RAPT Shares Sold by Medicxi Ventures Management Jersey LtdSeptember 16 at 5:21 AM | marketbeat.comRapt Therapeutics $RAPT Shares Bought by Comerica BankSeptember 15 at 3:10 AM | marketbeat.comRapt Therapeutics (NASDAQ:RAPT) Upgraded at Wall Street ZenSeptember 15 at 2:55 AM | marketbeat.comRapt Therapeutics (NASDAQ:RAPT) Receives Average Recommendation of "Moderate Buy" from AnalystsSeptember 13 at 2:55 AM | marketbeat.comRapt Therapeutics (NASDAQ:RAPT) Given Consensus Recommendation of "Moderate Buy" by BrokeragesSeptember 11, 2025 | americanbankingnews.comRapt Therapeutics (NASDAQ:RAPT) Stock Rating Upgraded by Wall Street ZenSeptember 8, 2025 | marketbeat.comRapt Therapeutics (NASDAQ:RAPT) Upgraded to Hold at Wall Street ZenSeptember 6, 2025 | americanbankingnews.comRAPT Therapeutics to Participate in Multiple Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comWall Street Analysts Think Rapt Therapeutics (RAPT) Could Surge 101.02%: Read This Before Placing a BetAugust 18, 2025 | zacks.comRapt Therapeutics (NASDAQ:RAPT) Receives Consensus Rating of "Moderate Buy" from AnalystsAugust 18, 2025 | marketbeat.comRapt Therapeutics price target raised to $9 from $8 at UBSAugust 12, 2025 | msn.comRapt Therapeutics (RAPT)'s Technical Outlook is Bright After Key Golden CrossAugust 12, 2025 | zacks.comRAPT Therapeutics Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | globenewswire.comWall Street Analysts Believe Rapt Therapeutics (RAPT) Could Rally 122.22%: Here's is How to TradeAugust 1, 2025 | zacks.comRAPT Therapeutics Unveils Plans for RPT904 DevelopmentJuly 30, 2025 | theglobeandmail.comRapt Therapeutics upgraded to Neutral from Underweight at JPMorganJuly 30, 2025 | msn.comJP Morgan Upgrades RAPT Therapeutics (RAPT)July 30, 2025 | msn.comLifeSci Capital Initiates Coverage of RAPT Therapeutics (RAPT) with Outperform RecommendationJuly 23, 2025 | msn.comRapt Therapeutics initiated with an Outperform at LifeSci CapitalJuly 23, 2025 | msn.comRapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's WhyJuly 15, 2025 | msn.comRapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's WhyJuly 15, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPLT, FENC, RAPT, and LYEL Company DescriptionsApplied Therapeutics NASDAQ:APLT$0.43 +0.01 (+3.37%) Closing price 04:00 PM EasternExtended Trading$0.43 0.00 (0.00%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.Adherex Technologies NASDAQ:FENC$8.85 +0.18 (+2.08%) Closing price 04:00 PM EasternExtended Trading$8.84 -0.01 (-0.17%) As of 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Lyell Immunopharma NASDAQ:LYEL$13.22 +0.09 (+0.69%) Closing price 04:00 PM EasternExtended Trading$13.29 +0.07 (+0.53%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Rapt Therapeutics NASDAQ:RAPT$17.63 +0.21 (+1.21%) Closing price 04:00 PM EasternExtended Trading$17.64 +0.02 (+0.09%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
